Table 3.
Concomitant IBD-related drug treatment at January 1, 2013.
| IBD related drug treatment | Total IBD population [n = 13 916] |
CD[n = 5690] | UC[n = 7409] | IBDU[n = 817] | ||||
|---|---|---|---|---|---|---|---|---|
| Aminosalicylates | Localcorticosteroids | Systemiccorticosteroids | Immunomodulators | Biologicals | ||||
| Aminosalicylates | 20.42% | 11.88% | 27.22% | 18.12% | ||||
| Immunomodulators | 5.41% | 9.68% | 2.40% | 2.94% | ||||
| Aminosalicylates | Immunomodulators | 3.83% | 3.66% | 3.93% | 4.16% | |||
| Systemic corticosteroids | 2.75% | 3.13% | 2.33% | 3.79% | ||||
| Biologicals | 2.59% | 4.83% | 1.04% | 1.10% | ||||
| Aminosalicylates | Local corticosteroids | 2.40% | 1.12% | 3.37% | 2.45% | |||
| Local corticosteroids | 2.08% | 2.88% | 1.47% | 2.08% | ||||
| Aminosalicylates | Systemic corticosteroids | 1.86% | 1.27% | 2.13% | 3.55% | |||
| Systemic corticosteroids | Immunomodulators | 0.86% | 1.41% | 0.47% | 0.61% | |||
| Aminosalicylates | Local corticosteroids | Systemic corticosteroids | 0.78% | 0.35% | 1.09% | 0.98% | ||
| Immunomodulators | Biologicals | 0.78% | 1.63% | 0.18% | 0.37% | |||
| Aminosalicylates | Systemic corticosteroids | Immunomodulators | 0.77% | 0.54% | 0.92% | 0.98% | ||
| Aminosalicylates | Biologicals | 0.59% | 0.56% | 0.63% | 0.37% | |||
| Local corticosteroids | Immunomodulators | 0.57% | 1.05% | 0.20% | 0.61% | |||
| Aminosalicylates | Local corticosteroids | Immunomodulators | 0.55% | 0.65% | 0.45% | 0.73% | ||
| Systemic corticosteroids | Biologicals | 0.37% | 0.74% | 0.07% | 0.61% | |||
| Local corticosteroids | Systemic corticosteroids | 0.37% | 0.47% | 0.30% | 0.24% | |||
| Aminosalicylates | Local corticosteroids | Systemic corticosteroids | Immunomodulators | 0.35% | 0.25% | 0.42% | 0.49% | |
| Aminosalicylates | Immunomodulators | Biologicals | 0.31% | 0.37% | 0.26% | 0.37% | ||
| Local corticosteroids | Systemic corticosteroids | Immunomodulators | 0.21% | 0.30% | 0.16% | - | ||
| Local corticosteroids | Biologicals | 0.16% | 0.25% | 0.07% | 0.37% | |||
| Systemic corticosteroids | Immunomodulators | Biologicals | 0.16% | 0.32% | 0.05% | - | ||
| Aminosalicylates | Systemic corticosteroids | Biologicals | 0.14% | 0.11% | 0.16% | 0.24% | ||
| Aminosalicylates | Local corticosteroids | Systemic corticosteroids | Biologicals | 0.13% | 0.07% | 0.16% | 0.24% | |
| Aminosalicylates | Systemic corticosteroids | Immunomodulators | Biologicals | 0.13% | 0.14% | 0.12% | 0.12% | |
| Aminosalicylates | Local corticosteroids | Systemic corticosteroids | Immunomodulators | Biologicals | 0.09% | 0.12% | 0.08% | - |
| Local corticosteroids | Immunomodulators | Biologicals | 0.09% | 0.19% | 0.01% | - | ||
| Aminosalicylates | Local corticosteroids | Immunomodulators | Biologicals | 0.06% | 0.09% | 0.04% | 0.12% | |
| Local corticosteroids | Systemic corticosteroids | Biologicals | 0.04% | 0.05% | 0.04% | - | ||
| Local corticosteroids | Systemic corticosteroids | Immunomodulators | Biologicals | 0.04% | 0.09% | - | - | |
| Aminosalicylates | Local corticosteroids | Biologicals | 0.03% | 0.05% | 0.01% | - | ||
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified.
Column cells marked in italic represent monotherapy.